Jean-François Rossignol, PhD, FRSC, MD, FRCPath, HonFFPM
Chief Medical & Science Officer
Dr. Rossignol is a co-founder of the Company and has served as Chief Medical and Scientific Officer and Chairman of the Board of Directors since its inception. He studied chemistry at the University of Paris where he received a doctorate degree in synthetic organic/medicinal chemistry, and then studied medicine specializing in Clinical Parasitology & Tropical Medicine under Prof. Raymond Cavier and Prof. Pierre Pène respectively. In 1973, he synthetized nitazoxanide, the first of a new class of antimicrobial agent effective against parasites, bacteria and viruses. Dr. Rossignol spent more than 30 years developing and registering drugs around the world. In 1979 he became responsible of the Tropical Medicine Program at SmithKline & French Laboratories where he developed the anthelmintic albendazole and the antimalarial halofantrine discovered at the Walter Reed Army Institute of Research. Both drugs received regulatory approvals from FDA and several countries in the world under the trade names of Albenza®/Zentel® and Halfan® respectively. Albendazole was later listed on the World Health Organization Essential Drug List.
In 1993, he re-initiated the development of nitazoxanide which became the first effective treatment for the protozoa Cryptosporidium parvum and received FDA approval under the trade name of Alinia®. More recently, his research led him to the development of a broad spectrum antiviral agent with first results of well controlled clinical trials in the treatment of norovirus and rotavirus diarrhea, chronic hepatitis C and influenza A and B viruses. Dr. Rossignol authored more than 100 peer-reviewed publications and holds 31 United States Patents on new drugs. He held faculty positions with the University of Paris and Stanford University in the United States as well as many other adjunct/visiting/clinical positions in the United States, the United Kingdom, Egypt and Peru. He also served as consultant and later expert in parasitic diseases at the World Health Organization between 1980 and 1991.
Marc S. Ayers
Manager and Chief Executive Officer
Mr. Ayers is a co-founder of the company. Prior to founding Romark, he spent seven years as a certified public accountant in the tax consulting practice of KPMG Peat Marwick in Tampa, Florida, and then five years as an investment banker, where he gained experience in working with the pharmaceutical industry. Mr. Ayers studied accounting, economics and finance, graduating summa cum laude with a Master's degree in Taxation from the University of Alabama in 1981.
Celine E. Rossignol
Executive Vice President and Chief Operating Officer
Celine joined Romark in September 2005 as Vice President of Marketing & Business Development and was named Executive Vice President and Chief Operating Officer in July 2006. She has over 17 years' experience in the healthcare/pharmaceutical industry. Before joining Romark, she was at IMS Health, where she held numerous sales and marketing positions, both in Europe and in the United States. She received her Bachelor of Science degree in Business Management from Rider University in New Jersey. She also completed an executive program on Strategic Marketing Management at Harvard Business School.
Chief Financial Officer
Brian heads the company's finance and accounting functions. He graduated from the University of Nebraska with a Bachelor of Science degree in Business Administration. He spent eight years as a certified public accountant in the audit practice of KPMG Peat Marwick in Lincoln, Nebraska, and Tampa, Florida. He is a licensed CPA in the State of Florida.